BryoLogyx Inc (www.bryologyx.com) is advancing a new class of cancer immunotherapeutics. The Company’s lead compound, bryostatin-1, is being developed as a cornerstone of cancer immunotherapies to amplify the immune response, increase treatment durability, and improve outcomes. BryoLogyx has exclusive rights from Stanford University to intellectual property covering the synthesis and methods of use of bryostatin-1 in cancer and other diseases. Bryostatin-1 is poised to enter initial proof-of-concept trials in immune-oncology (IO) in late 2020 through a collaboration with the National Cancer Institute (NCI).
INVESTMENT HIGHLIGHTS
Potential cornerstone therapy in immuno-oncology
Clinical proof-of-concept study at NCI to expected to begin Fall 2020
Extensive NCI clinical data providing fundamental data supporting bryostatin-1’s safety
Pre-clinical data pointing to bryostatin-1's potential for antigen upregulation in immuno-oncology
Seasoned team of biopharma executives and advisors
INVESTMENT HIGHLIGHTS
Potential cornerstone therapy in immuno-oncology
Clinical proof-of-concept study at NCI to expected to begin Fall 2020
Extensive NCI clinical data providing fundamental data supporting bryostatin-1’s safety
Pre-clinical data pointing to bryostatin-1's potential for antigen upregulation in immuno-oncology
Seasoned team of biopharma executives and advisors
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Bryostatin-1
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Multiple (specific to antigens and IO agents)
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
